The Monash Health Department of Oncology provides more than 1.5 million residents of southern Melbourne with access to world leading cancer treatment over four locations within the Monash Health service:

Moorabbin Hospital: Breast cancer, GI cancer, GU cancer, Lung cancer, Head & Neck cancer, Gynecological cancer, Urologic cancer

Dandenong Hospital: General Oncology, Geriatric Oncology

Casey Hospital: General Oncology

Monash Health Translation Precinct (MHTP building Level 3). Monash Medical Centre, Clayton: Cancer Clinical Trials

Monash Medical Centre Clayton: Neuro-oncology cancer

Our Services

Cancer patients receive care from diagnosis to treatment and follow-up support. Through collaborative multidisciplinary team framework we provide the Medical Oncology aspect of cancer care, integrating with teams from surgical and radiation oncology and Palliative and Supportive care.

Our Staff

Department Head

Prof. Eva Segelov MBBS (Hons 1) PhD FRACP

Professor/Director of Oncology
Gastrointestinal Cancers Neuroendocrine Tumours

Senior Leadership Team

A/Prof. Arun Azad MBBS FRACP PhD
Head of Oncology Clinical Trials
Genitourinary Cancer

A/Prof. Michael Franco MBBS FRACP FAChPM
Head of Oncology Operations & Education
Palliative Medicine Breast & GI Cancer

A/Prof. Jake Shortt BMedSc MBChB FRACP FRCPA PhD
Head of Translational Research

Dr. Michelle White MBBS GDipPallMed FRACP
Head of Oncology Quality & Safety, Breast Cancer

Senior Medical Staff

A/Prof. Andrew Strickland MBBS FRACP
Gastrointestinal Cancers

Dr. Ben Markman MBBS FRACP
Phase 1 Trials, Lung, Gastrointestinal Cancers

Dr. Daphne Day MBBS (Hons), FRACP
Breast & Head and Neck Cancer and Phase 1 trials

Dr. David Pook BMedSci (Hons) MBBS FRACP MD
Genitourinary Cancer

Dr. Edmond Kwan MBBS FRACP
Genitourinary Cancer

Dr. Geraldine Goss MBBS FRACP MD MMED
Gynaecological Cancers

Dr. Marion Harris MBBS FRACP
Director of Familial Cancer, GI and Breast Cancer

Dr. Muhammad Alamgeer MBBS MD MRCP FRACP
Lung, Head & Neck Cancer

Dr. Ranjana Srivastava MBBS FRACP
Breast, Gastrointestinal Cancers, Geriatric Oncology

Ms. Karen Gillett
Oncology Research Manager

Mrs. Irina Arzhintar
Study Coordinator

Ms. Cheryl-Ann Hawkins
Study Coordinator

Ms. Penny McGuire
Study Coordinator

Ms. Chris Brooks
Study Coordinator

Ms. Louise Davis
Study Coordinator

Ms. Chris Poole
Study Coordinator

Ms. Laima Muceneikas
Study Coordinator

Ms. Lindsay Thompson
Study Coordinator

Ms. Shelley Firth
Study Coordinator

Ms. Lisa Robinson
Study Coordinator

Ms. Kim Brewin
Study Coordinator

Ms. Frances Bishop
Study Coordinator

Ms. Stephanie Kaladis
Study Coordinator

Ms. Joanna Maggs
Ethics Submission Specialist

Ms. Sabah Saad
Ethics Submission Specialist

Ms. Isabelle Nehma
Study Coordinator

Ms. Joyce Zheng
Clinical Trial Assistant

Ms. Kanan Gill Sharma
Clinical Trial Assistant

Ms. Lauren Curtain
Clinical Trial Assistant

Ms. Sarah Niazmand
Clinical Trial Assistant

Ms. Dixita Desai
Laboratory Assistant

Ms. Annette McClellan
Oncology department Secretary/PA to Professor Segelov.
E: Annette.McClellan@monashhealth.org
P: +61 3 8572 2392

Ms. Julie Kavanagh
Oncology Research Administration Assistant 
E: Julie.Kavanagh@monashhealth.org
P: +61 3 8572 2935

Dr. Maja Green PhD, MSc,BSc (Hons)
Post Doctorate Fellow


Department Publications


Singh S, Moody L, Lui N, Fischer H, Austin P, Chan D, Segelov E. Patterns of recurrence after curative resection for gastrointestinal neuroendocrine tumours: a population based study identifying timing of relapse and relation to surveillance imaging. JAMA Oncology. Accepted for publication Dec 27 2017. Senior author


Roy AC, Wattchow D, Astill D, Singh S, Pendlebury S, Gormly K, Segelov E. Uncommon Anal Neoplasms. Surgical oncology clinics of North America. anal cancer edition Surgical Oncology Clinics of North America 26 2017 Jan 31;26(1):143-61.invited chapter editor and Senior author, Impact factor 2

Annala M, Nappi L, Azad A A, Mo F, Fazli L, Chi KN, Wyatt AW. Molecular Dissection of Complete Response to Receptor Tyrosine Kinase Inhibition in Type II Papillary Renal Cell Carcinoma. Clinical genitourinary cancer. 2017 Feb 1;15(1):e145-50.

Wein L, Rowe C, Brady B, Handolias D, Lipton L, Pook D , Stanley R, Haines I. Prevalence of systemic anticancer therapy for patients within the last 30 days of life: experience in a private hospital oncology group. Internal medicine journal. 2017 Mar 1;47(3):280-3.

Srivastava R. The Interpreter. N Engl J Med. 2017 Mar 2;376:812-3

Sandler CX, Goldstein D, Horsfield S, Bennett BK, Friedlander M, Bastick PA, Lewis CR, Segelov E , Boyle FM, Chin MT, Webber K. Randomized evaluation of cognitive-behavioral therapy and graded exercise therapy for post-cancer fatigue. Journal of pain and symptom management. 2017 May 11.

Chan DL, Segelov E, Wong RS, Smith A, Herbertson RA, Li BT, Tebbutt N, Price T, Pavlakis N. Epidermal growth factor receptor (EGFR) inhibitors for metastatic colorectal cancer. The Cochrane database of systematic reviews. 2017 Jun 27;6:CD007047.

Strosberg JR, Halfdanarson TR, Bellizzi AM, Chan JA, Dillon JS, Heaney AP, Kunz PL, O’Dorisio TM, Salem R, Segelov E, Howe JR. The North American Neuroendocrine Tumor Society Consensus Guidelines for Surveillance and Medical Management of Midgut Neuroendocrine Tumors. Pancreas. 2017 Jul 1;46(6):707-14.

Chan D, Segelov E, Ferone D, Albertelli M, Pavlakis N,  Singh S. Escalated dose somatostatin analogues for anti-proliferative effect in GEP-NETS: A systematic review. Endocrine 2017 Jul 19:1-0. contributing author, Impact factor 3.1

Kwan EM, Beck S, Amir E, Jewett MA, Sturgeon JFG, Anson-Cartwright L, Chung PWM, Warde PR, Moore MJ, Bedar PL, Tran B. (in press).  Impact of granulocyte-colony stimulating factor on bleomycin-induced pneumonitis in chemotherapy-treated germ cell tumours. Clin Genitourin Cancer. doi: 10.1016/j.clgc.2017.08.012

Segelov E, Lordick F, Goldstein D, ChantrillL, Croagh D, Lawrence B, Arnold D, Chau I, Obermannova R, Price T. Current challenges in optimizing systemic therapy for patients with pancreatic cancer: Expert perspectives from the Australian Gastrointestinal Trials Group with invited international faculty. Expert Review in Anticancer Therapy. Published online Sept 5 2017 doi.org/10.1080/14737140.2017.1369882 . First author, Impact factor 2

Chan DLH, Segelov E, Wong RSH, Smith A, Herbertson RA, Li B, Tebbutt N, Price T, Pavlakis N. Epidermal growth factor receptor (EGFR) inhibitors for metastatic colorectal cancer. Cochrane Database of Systematic Reviews 2017 Issue 6, Art: CD007047.Contributing author, impact factor 6.1

Lam M, Tran B, Beck S, Tie J, Herath D, Whittle J, Kwan EM, Fox S, Fellowes A, Ananda S, Lipton L, Gibbs P, Rosenthal M, Desai J. (in press). Precision medicine using a clinician-directed, tailored approach to molecular profiling. Asia Pac J Clin Oncol. doi: 10.1111/ajco.12787

Chan D, Segelov E, Singh S.Update on the use of everolimus in the management of metastatic neuroendocrine tumors of gastrointestinal origin. Invited article; Therapeutic advances in gastroenterology; 2017: 10 (1) 132-141. One of three contributingauthors, Impact factor 5 doi:10.1177/1756283X16674660

Templeton, D. J. , Roberts, J. M. , Poynten, I. M. , Law, C. , Hillman, R. J. , Farnsworth, A., Fairley, C. K.  , Tabrizi, S. N. , Grulich, A. E. , Jin, F. , Acraman, B. , Carr, A. , Carroll, S. , Cooper, D. , Cornall, A. , Crampton, L. , Fairley, K. , Feeney, L. , Fraissard, E. , Howard, K. & 21 others Law, M., Machalek, D. A., McCaffery, K., McGrath, P., Mellor, R., Norris, R., O'Dwyer, M., Pendlebury, S., Petoumenos, K., Phillips, S., Poynten, I. M., Prestage, G., Richards, A., Schema, L., Seeds, D., Segelov E., Templeton, D., Thurloe, J. K., Tong, W. W. Y., Varma, R. On behalf of the SPANC Study Team Prevalence and predictors of unsatisfactory anal cytology tests in a cohort of gay and bisexual men in Sydney, Australia: Baseline findings from the Study of the Prevention of Anal Cancer (SPANC). 2017 European Journal of Cancer Prevention. 26, 3, p. 212-216 


For 2016 publications click here

Department Abstracts


Segelov E, Williams D, Chia J, Sieber O. COX2 and HLA immunohistochemical (IHC) staining in colorectal tumour samples from patients participating in the ASCOLT clinical trial of adjuvant aspirin therapy. Accepted for ASCO GI 2018.

Clarke S,  Burge M,  Feeney K, Jones K, Gibbs P, Molloy M, Marx G, Price T, Reece W, Segelov E, Tebbutt N.  Results from an Australian translational study to evaluate the prognostic role of inflammatory markers in patients with mCRC treated with bevacizumab [ASCENT]. Accepted for ASCO GI 2018


Poon P, Shaw T, Franco M, Runacres F, William L, Yoong J. Successful large volume ‘lymphocentesis’ for refractory lymphoedema in lower and upper limbs. Internal Medicine Journal. 2017 May 1;47(5):607-.

Optimal Care Pathways for cancer patients

The optimal cancer care pathways (OCPs) describe the optimal cancer care for specific tumour types. They map the patient journey, aiming to foster an understanding of the whole pathway and its distinct components to promote quality cancer care and patient experiences.

Cancer: What to Expect? Information for patients at http://www.cancerpathways.org.au/

Information for clinicians at http://www.cancervic.org.au/for-health-professionals/optimal-care-pathways

 Cancer prevention

Between 30-50% of all cancer cases are preventable. Prevention offers the most cost-effective long-term strategy for the control of cancer. National policies and programmes should be implemented to raise awareness, to reduce exposure to cancer risk factors and to ensure that people are provided with the information and support they need to adopt healthy lifestyles.


 Updated January 2018


 Contacts and Locations


Moorabbin Hospital
823-865 Centre Rd
Bentleigh East
+61 3 9928-8120

Clinical Trials Centre
Level 3, MHTP Building 
Monash Health
246 Clayton Rd, Clayton
+ 61 3 8572 2427

Dandenong Hospital
David St, Dandenong
+61 3 9554-8977

Casey Hospital
62-70 Kangan Drive
Berwick 3806
+61 3 8768 1200


Monash Oncology In the News

Please click on the links below to see our Oncology department at work

Cancer Communication

Scalp cooling machines

Clinical Trials at Monash